W22--Lungs & Beyond

Chair(s)

• AL

  Allison Love, MD, FRCPC

  University of British Columbia
• 

  Sid Kapnadak, MD (he/him/his)

  University of Washington School of Medicine

This workshop highlights clinical studies evaluating real-world pulmonary and extra-pulmonary outcomes in the CFTR modulator era.

Presentations:

• 10:15 AM – 12:15 PM ET

  W22.1- Adherence to Elexacaftor/Tezacaftor/Ivacaftor and clinical outcomes in People with Cystic Fibrosis (CF) – the RECOVER Study
  

  Speaker: Paul McNally – RCSI University of Medicine and Health Sciences
• 10:15 AM – 12:15 PM ET

  W22.2- Effect of Elexacaftor-Tezacaftor-Ivacaftor on Long-Term Lung Function and BMI Trajectories
  

  Speaker: George M. Solomon, MD – University of Alabama at Birmingham, Birmingham, AL USA
• 10:15 AM – 12:15 PM ET

  W22.3- Liver disease outcomes in people with CF after two years of Elexacaftor/Tezacaftor/Ivacaftor – Results from the RECOVER trial
  

  Speaker: Paul McNally – RCSI University of Medicine and Health Sciences
• 10:15 AM – 12:15 PM ET

  W22.4- Triple CFTR modulator combination improves glucose tolerance in adolescents with cystic fibrosis. Data from the French observational pediatric study MODUL-CF
  

  Speaker: Alfonso Galderisi, MD, PhD (he/him/his) – Yale University, Department of pediatrics, New Haven, CT, United States
• 10:15 AM – 12:15 PM ET

  W22.5- Maternal and fetal outcomes in the era of CFTR modulators (MAYFLOWERS) study: interim results
  

  Speaker: Raksha Jain, MD, MSc (she/her/hers) – University of Texas Southwestern Medical Center